A secondary analysis of the CASSINI trial finds that rivaroxaban is an effective thromboprophylactic for patients with pancreatic cancer receiving systemic therapy.
Two new studies show that oral anticoagulants and prescreening for blood clots before starting cancer treatment may help prevent blood clots in high-risk cancer patients.
Since Alok Khorana, MD, introduced this tool a decade ago, it has been validated multiple times in different countries and incorporated into a number of society guidelines.
Post-operative VTEs can be deadly. A nurse-led study at Cleveland Clinic compared the effectiveness of written instructions versus a multimethod educational approach to teach patients about VTEs.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
The rate of VTE recurrence in patients with GPA is similar to that of first VTE recurrence in patients with cancer.
With an array of VTE chemoprophylactic agents – from low-molecular-weight heparin to warfarin to newer anticoagulants – available for patients undergoing TJA, how do you choose? Is simple ASA enough?
A Cleveland Clinic-led study found that higher levels of circulating tissue factor serve as a biomarker for recurrent venous thromboembolism — a common, underestimated problem for cancer patients.
Based on study of more than 28,000 TJA patients, presurgical ABO blood group testing looks like an inexpensive way to identify patents at increased risk for symptomatic postoperative VTE.
After an episode of venous thromboembolism without clear provocation, it’s reasonable to suspect undiagnosed cancer as an underlying factor. But how thoroughly (and expensively) should physicians search for occult underlying malignancy? A Cleveland Clinic expert weighs in on new research findings.